Diligence memo · auto-generated · as of July 3, 2026
Intervene Immune, Inc.
Intervene Immune, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Intervene Immune, Inc. operates in Biotechnology, based in MANHATTAN BEACH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Intervene Immune, Inc. has raised $471K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $471K on 2013-11-15.
Most recent recorded round closed around 2013-11-15.
Valuation (modeled)modeled
Provath models Intervene Immune, Inc. at approximately $26M (range $251K–$295M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.64× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 10% of Biotechnology peers (4293 compared).
Modeled value ranks above 32% of those peers.
Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.